John H. Sampson, MD, PhD, MBA, MHSc

John H. Sampson, MD, PhD, MBA, MHSc, chief, Division of Neurosurgery, Duke University Medical Center, discusses rindopepimut eliminating brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII). He says tumors that do not express EGFRvIII will continue to grow and rindopepimut alone would not be effective.

In brain cancer patients where rindopepimut is not effective alone, Sampson says additing treatments like checkpoint inhibitors may allow the immune system to attack the tumor cells better.

Videos

Dr. John H. Sampson discusses rindopepimut elimiting brain tumor cells that express the epidermal growth factor receptor mutation variant III (EGFRvIII).

John H. Sampson, MD, PhD, MBA, MHSc | Authors

Articles

Dr. John H. Sampson on the Use of Rindopepimut in Brain Cancer